The influence of treatment with somatostatin analogues on morphology, proliferative and apoptotic activity in GH-secreting pituitary adenomas

Melmed, 1998, Current treatment guidelines for acromegaly, J. Clin. Endocrinol. Metab., 83, 2646, 10.1210/jc.83.8.2646 Swearingen, 1998, Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly, J. Clin. Endocrinol. Metab., 83, 3419, 10.1210/jc.83.10.3419 Epaminonda, 2001, Efficacy of radiotherapy in normalizing serum IGF-I, acid-labile subunit (ALS) and IGFBP-3 levels in acromegaly, Clin. Endocrinol. (Oxf), 55, 183, 10.1046/j.1365-2265.2001.01294.x Lamberts, 1985, Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995, N. Engl. J. Med., 313, 1576, 10.1056/NEJM198512193132504 Melmed, 1995, Clinical review 75: recent advances in pathogenesis, diagnosis, and management of acromegaly, J. Clin. Endocrinol. Metab., 80, 3395, 10.1210/jc.80.12.3395 Marek, 1994, Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide, Eur. J. Endocrinol., 131, 20, 10.1530/eje.0.1310020 Amato, 2002, Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly, Clin. Endocrinol. (Oxf), 56, 65, 10.1046/j.0300-0664.2001.01438.x Attanasio, 2001, GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide, J. Endocrinol. Invest., 24, 209, 10.1007/BF03343849 Baldelli, 2000, Two-year follow-up of acromegalic patients treated with slow release lanreotide (30mg), J. Clin. Endocrinol. Metab., 85, 4099, 10.1210/jc.85.11.4099 Biermasz, 1999, Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls, J. Clin. Endocrinol. Metab., 84, 3551, 10.1210/jc.84.10.3551 Kristof, 1999, Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study, Acta Neurochir. (Wien), 141, 399, 10.1007/s007010050316 Colao, 1997, Effect of octreotide pretreatment on surgical outcome in acromegaly, J. Clin. Endocrinol. Metab., 82, 3308, 10.1210/jc.82.10.3308 Stevenaert, 1996, Presurgical Octreotide: treatment in acromegaly, Metabolism, 45, 72, 10.1016/S0026-0495(96)90088-8 Thapar, 1997, Antiproliferative effect of the somatostatin analogue octreotide on growth hormone-producing pituitary tumors: results of a multicenter randomized trial, Mayo Clin. Proc., 72, 893, 10.1016/S0025-6196(11)63358-2 Saitoh, 1997, Absence of apoptosis in somatotropinomas treated with octreotide, Acta Neurochir. (Wien), 139, 851, 10.1007/BF01411403 Kulig, 1999, Apoptosis in nontumorous and neoplastic human pituitaries: expression of the Bcl-2 family of proteins, Am. J. Pathol., 154, 767, 10.1016/S0002-9440(10)65323-0 Losa, 2001, Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas, J. Clin. Endocrinol. Metab., 86, 5194, 10.1210/jc.86.11.5194 Cerman, 1994, The use of immunohistochemistry in biopsy of pituitary adenomas, Funct. Develop. Morph., 4, 211 Cerman, 1994, Immunohistochemical detection of human pituitary homones, Funct. Develop. Morph., 4, 209 Spinas, 1987, Pre-operative treatment of 5 acromegalics with a somatostatin analogue: endocrine and clinical observations, Acta Endocrinol. (Copenh), 114, 249, 10.1530/acta.0.1140249 Ezzat, 1994, Morphological effects of octreotide on growth hormone-producing pituitary adenomas, J. Clin. Endocrinol. Metab., 79, 113, 10.1210/jc.79.1.113 George, 1987, Effect of SMS 201-995, a long-acting somatostatin analogue, on the secretion and morphology of a pituitary growth hormone cell adenoma, Clin. Endocrinol. (Oxf), 26, 395, 10.1111/j.1365-2265.1987.tb00796.x Sautner, 1993, Effects of octreotide on morphology of pituitary adenomas in acromegaly, Pathol. Res. Pract., 189, 1044, 10.1016/S0344-0338(11)80678-3 Barkan, 1988, Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate, J. Clin. Endocrinol. Metab., 67, 1040, 10.1210/jcem-67-5-1040 Schwartzman, 1993, Apoptosis: the biochemistry and molecular biology of programmed cell death, Endocr. Rev., 14, 133 Pagliacci, 1991, Inhibition of human breast cancer cell (MCF-7) growth in vitro by the somatostatin analog SMS 201-995: effects on cell cycle parameters and apoptotic cell death, Endocrinology, 129, 2555, 10.1210/endo-129-5-2555 Imam, 1997, Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs, Acta Oncol., 36, 607, 10.3109/02841869709001323 Gruszka, 2001, Anti-tumoral action of octreotide and bromocriptine on the experimental rat prolactinoma: anti-proliferative and pro-apoptotic effects, Neuroendocrinol. Lett., 22, 343 Landolt, 1991, Growth, cell proliferation, and prognosis of pituitary adenomas, 169